Research
Hormonal
GLP-1 RA use is associated with increased risk of gallbladder or biliary diseases for longer durations (RR, 1.40; 95% CI, 1.26-1.56) compared to shorter durations (RR, 0.79; 95% CI, 0.48-1.31).
Clinicians should monitor patients on GLP-1 RAs for gallbladder issues, especially with prolonged use.
StrongSupportsmedium confidence
GLP-1 RA use was associated with higher risks of gallbladder or biliary diseases at longer duration of use (RR, 1.40; 95% CI, 1.26-1.56) compared with shorter duration (RR, 0.79; 95% CI, 0.48-1.31).
Why this rating
Based on a systematic review and meta-analysis of randomized clinical trials.
Source
Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
Liyun He et al. · JAMA Internal Medicine · 2022
Meta-analysisCited 285×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →